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Atherosclerosisa b s t r a c t
Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of low-density lipo-
protein receptor (LDLRs) molecules expressed on the cell surface. Gene inactivation of PCSK9
reduces the areas of atherosclerotic lesions in mice, and the effect is mainly dependent on LDLRs.
Furthermore, a positive relationship between PCSK9 and cholesterol accumulation in the wall of
the aorta has been established. However, the mechanism remains unknown. As PCSK9 is mainly
expressed in atherosclerotic plaque and in the liver, we hypothesize that PCSK9 might increase oxi-
dized LDL uptake and impair macrophage-mediated reverse cholesterol transport, contributing to
the development of atherosclerosis.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Atherosclerosis (AS) is the leading cause of morbidity and mor-
tality in industrialized countries. Macrophage uptake of oxidized
low-density lipoprotein (oxLDL) facilitates the formation of foam
cells, which contribute to the progression of atherosclerotic lesions
[1]. Reverse cholesterol transport (RCT) prevents the development
of AS via multiple steps involving cholesterol efﬂux to high-density
lipoproteins (HDLs), cholesterol uptake by the liver, and ultimately,
hepatic cholesterol excretion into the feces [2].
Proprotein convertase subtilisin/kexin type 9 (PCSK9) contains
a signal sequence, a prodomain, a catalytic domain and a C-termi-
nal domain [3]. It has been clearly established that PCSK9 has two
major biological functions: degradation of low-density lipoprotein
receptors (LDLRs) in the liver and regulation of neural apoptosis
[3]. In addition, many studies have shown that PCSK9 mutations,
associated with a speciﬁc hypercholesterolemic phenotype, con-
tribute to the development of atherosclerosis and CHD events
[4,5]. We do not further discuss the role of PCSK9 in neuronal
apoptosis further because the present hypothesis focuses on PCSK9
as it pertains to cardiovascular disease, and is limited to the role
PCSK9 plays in LDLR degradation. Previously, the vast majority of
studies focused on the role of PCSK9 in the liver; however,
increasing evidence for the expression and function of PCSK9 inatherosclerotic lesions has emerged. Three major arterial wall cells
types, including monocyte/macrophages, smooth muscle cells
(SMCs), and endothelial cells, exists in atherosclerotic lesions [6].
Two independent groups have reported detecting PCSK9 in athero-
sclerotic plaques. However, information regarding the location of
PCSK9 is inconsistent [7,8]. The study of Ferri and colleagues [7]
indicated that PCSK9 is expressed in SMCs rather than in macro-
phages. They determined that SMCs secreted functionally active
PCSK9, which could reduce LDLR expression in the surface of mac-
rophages in a paracrine manner.
Another group suggested that neural apoptosis regulate conver-
tase 1 (NARC-1), which is encoded by the PCSK9 gene, located not
only in both THP-1-derived macrophages, but also in atheroscle-
rotic lesions. They are especially expressed in the cytoplasm and
plasma membrane of foam cells [9,10]. Furthermore, oxLDL dose-
dependently upregulated the expression of PCSK9 in THP-1-de-
rived macrophages [11]. In addition, although no direct evidence
exists as to the expression of PCSK9 in endothelial cells, PCSK9 siR-
NA was found to inhibit oxLDL-mediated apoptosis in human
umbilical vein endothelial cells (HUVECs) [8]. Therefore, these
ﬁndings indicated the potential role of PCSK9 in the development
of atherosclerotic plaque.
In humans, PCSK9 gain-of-function (D374Y PCSK9) leads to
autosomal dominant hypercholesterolemia, whereas the absence
of functional PCSK9 results in approximately sevenfold lower lev-
els of LDL-C. This suggests that reducing PCSK9 levels may protect
against atherosclerosis. Likewise, the transgenic mice expressing
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oped extensive atherosclerotic lesions in the aorta when fed a
high-cholesterol diet [5]. Conversely Denis et al. [12] demonstrated
that gene inactivation of PCSK9 reduced aortic cholesterol accumu-
lation and the areas of atherosclerosis lesion in apolipopro-
tein(apo)E/ mice, which indicates a direct relationship between
PCSK9 and the development of atherosclerosis. Thus, we hypothe-
size that PCSK9 contributes to the development of atherosclerosis,
as evidenced by the following aspects: (1) macrophage cholesterol
uptake, (2) cholesterol efﬂux, (3) hepatic cholesterol uptake, and
(4) intestinal cholesterol absorption.
2. Macrophage PCSK9 increases cholesterol uptake and foam
cell formation
Early research has indicated that cholesterol accumulation in
atherosclerotic plaques can be due to either increased circulating
LDL or rate of LDL transport across endothelial cells [13]. Hepatic
PCSK9 degrades LDLR, resulting in higher plasma LDL. Wu et al.
[8] demonstrated that PCSK9 siRNA inhibited oxLDL-induced HU-
VEC apoptosis, decreasing the permeability of the endothelial cells.
Thus, it is speculated that PCSK9 enhances the rate of LDL transport
into the subendothelial space. In addition, PCSK9 is secreted by hu-
man SMCs and is capable of functionally reducing LDLR expression
in cell surface ofmacrophages [7]. Furthermore, the downregulation
of LDLR expression signiﬁcantly inhibited LDL uptake in the macro-
phage cell line J774 [7]. Therefore, PCSK9 is the possible determi-
nant of LDL retention within the subendothelia of arterial walls.
Macrophages are liable to oxidatively modify accumulated LDL
to a form that is easily recognized by scavenger receptors (SRs)
[14]. Moreover, the ability of LDL oxidation in peritoneal macro-
phages derived from LDLR/ mice was somewhat greater than
that in macrophages from C57BL/6 mice [15]. Thus, the reduction
of cell surface LDLR expression in macrophage by PCSK9 may con-
tribute to the acceleration of the rate of LDL oxidation and increase
oxLDL accumulation in arterial walls.
Macrophages in the arterial intima take up modiﬁed LDL
through various SRs, principally SR CD36 and SR-A [14]. It has been
shown that when THP-1-derived macrophages are transfected
with PCSK9 siRNA, intracellular cholesterol accumulation after
incubation with oxLDL for 24 h was less than that in a control
group [16].Subsequently, these authors found that CD36 mRNA
expression in the PCSK9 siRNA transfection group was signiﬁcantly
lower than that in the control group [16], indicating that PCSK9 in-
creases macrophage CD36 expression. In addition, PCSK9 promotes
the aggregation of LDL, which is prone to modiﬁcation, then accu-
mulated oxLDL upregulate the expression of CD36 [17].
Denis et al. [12] demonstrated higher cholesterol accumulation
and severe aortic lesions in transgenic PCSK9 mice compared to
wide-type controls. In contrast, PCKS9-knockout mice accumulated
fourfold less aortic cholesterol than the wild-type controls did [12].
Based on this observation,we speculate that PCSK9might accelerate
the uptake of oxLDL partly via CD36, contributing to macrophage
cholesterol accumulation and atherosclerotic lesion formation.
3. PCSK9 impairs macrophages cholesterol efﬂux
Cholesterol efﬂux is the ﬁrst step of RCT. Cellular cholesterol ef-
ﬂux to apoAI occurs through the ATP-binding cassette family A1
(ABCA1), while free cholesterol efﬂux to mature HDL particles in-
volves both SR class B type I (SR-BI) and the ABCG1 [1].
On one hand, Zhou et al. [18] ﬁrstly demonstrated that LDLRs
play a critical role in regulating cholesterol efﬂux and ABCA1
expression in macrophages. In their study, LDLR/ macrophages
manifested lower basal levels of ABCA1, ABCG1, and cholesterolefﬂux than wide-type cells. Moreover, oxLDL induced signiﬁcantly
higher ABCA1 expression in wild-type macrophages than in LDLR-
knockout cells [18]. Therefore, the lack of LDLR from PCSK9 expres-
sion in atherosclerotic lesions may impair macrophage expression
of ABCA1 and ABCG1. In addition, the following data support the
repression of PCSK9 in SR-BI-mediated macrophage cholesterol ef-
ﬂux. The ﬁrst possible reason is that oxLDL might play dual roles in
macrophage lipid accumulation. PCSK9 facilitates the accumula-
tion of oxLDL in the subendothelial space, which not only aug-
ments the functional expression of CD36, promoting lipid
accumulation in macrophages [17], but also decreases SR-BI
expression in fully differentiated macrophages through an un-
known mechanism.
Therefore, PCSK9 expression in atherosclerotic lesions inhibits
LDLR activity in macrophages, which leads to repressed macro-
phage expression of ABCA1, ABCG1, and SR-BI, and impaired cho-
lesterol efﬂux, promoting lipid retention within macrophages.
4. PCSK9 blocks hepatic cholesterol uptake
Cholesterol is transported in the circulation in HDL and apoB-
containing lipoproteins, which are taken up and metabolized with-
in the liver hepatocytes [19]. PCSK9 impairs hepatic cholesterol up-
take through two pathways.
Hepatic LDLRs internalize more than half of the apoB-associated
cholesterol, which undergoes endocytosis and degradation within
lysosomes [20]. However, PCSK9 can degrade LDLR molecules ex-
pressed on the surface of hepatocytes. Thus, PCSK9 blocks choles-
terol uptake by inhibiting the pathway of LDLR-mediated
lipoprotein binding and internalization. In addition, apoB-associ-
ated cholesterol can also be internalized by LDLR related protein
(LRP) [21]. The observation suggests that PCSK9 may involve the
degradation of LRP in rat liver cell [22]. Despite cholesterol uptake
by this pathway being complex, PCSK9 may impair the uptake of
apoB-containing lipoproteins possibly by disrupting LRP-mediated
endocytosis.
Alternatively, cholesterols in the HDL are delivered to the liver
via cholesteryl ester transfer protein (CETP), converted to bile salts
and eliminated through the gastrointestinal tract [23]. CETP has a
well-established role in mediating the transfer of cholesteryl esters
from HDL to apoB-containing lipoproteins (LDL or very low-density
lipoprotein) in exchange for triglycerides, with subsequent uptake
in the liver via the hepatic LDLR [24]. Animal studies have sup-
ported the notion that CETP facilitates RCT in wild-type mice but
decreases RCT ﬂux in LDLR-deﬁcient mice [25]. The impact of CETP
on RCT, and thus potentially on cardiovascular disease, may there-
fore vary according to the hepatic LDLR expression and the efﬁ-
ciency of LDL clearance [25]. Without direct evidence
demonstrating the impact of PCSK9 on the CETP-mediated RCT
pathway, as PCSK9 reduces hepatic LDLR levels, we may speculate
that it negatively inﬂuences the rate of CETP-mediated RCT.
5. PCSK9 inhibits intestinal cholesterol absorption
Intestinal cholesterol absorption is a major determinant of RCT
from peripheral tissue, such as macrophages. The liver secretes the
cholesterol in apoB-containing lipoproteins or HDL, which are spe-
ciﬁcally targeted to the small intestine. After LDLR internalization,
the cholesterol is trafﬁcked across the enterocytes to the brush
border membrane and efﬂuxed into the intestinal lumen by choles-
terol transporter.
Even though hepatic LDLRs are the primary regulator of circu-
lating LDL, there is evidence that PCSK9 plays a role in regulating
intestinal cholesterol homeostasis via the degradation of LDLRs
in entrocytes, inhibiting intestinal cholesterol absorption. Schmidt
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PCSK9 or adenoviral overexpression PCSK9 not only caused a sig-
niﬁcant reduction of hepatic LDLR levels, but also effectively re-
duced LDLRs in extrahepatic tissues such as intestinal tissue,
although not as robustly as in the liver. In addition, studies on
LDL removal have consistently suggested that approximately 10%
of LDLR-mediated LDL clearance occurs in the intestine [27]. By
depleting LDLRs in the basolateral side of enterocytes, which are
in contact with the plasma, the secreted PCSK9 limits the capture
of LDL particles in the intestine. This results in increased accumu-
lation of cholesterol in the plasma, and is not conducive to choles-
terol removal via intestinal transport [27]. However, the extent of
this effect is still unclear. Secondly, PCSK9 expression is primarily
located in two places in the intestine: the endoplasmic reticulum
and golgi of epithelial cells, and the apical and basolateral sides
of enterocytes [28]. May et al. [28] demonstrated that PCSK9/
mice tend to accumulate fewer lipids in the proximal and medial
parts of their intestine compared to wild-type mice, suggesting
that lipid uptake could be defective in these areas. Thus, it appears
that PCSK9 expression negatively regulates intestinal cholesterol
absorption and impairs cholesterol homeostasis in enterocytes.
6. Inconsistencies and future directions
Several studies have investigated the relationship between
PCSK9 and plasma HDL-C levels, but have generated inconsistent
results. Lalanne et al. [29] demonstrated that adenovirus-mediated
overexpression of PCSK9 in C57BL6/J mice led to no signiﬁcant
change in HDL-C levels, while there was 1.3-fold elevation in the
HDL-C levels in PCSK9-overexpressing mice [30]. In addition, there
was an increased trend towards plasma HDL-C and apoA1 levels
with PCSK9 antibody treatment [31,32]. However, an increasing
number of investigations have showed that the best method of
assessing the rate of centripetal cholesterol ﬂux through the mac-
rophage RCT pathway is not the HDL-C levels, but HDL functional-
ity, and that there are inherent limitations to the static
measurement as a surrogate for overall HDL functionality [19].
Therefore, further studies are needed, especially in the relationship
of PCSK9 and HDL functionality.
This hypothesis provides a new insight into PCSK9 and suggests
an innovative therapeutic strategy against atherosclerosis. How-
ever, because it is primarily based on speculations and to some ex-
tent, lacks sound scientiﬁc data that support the hypothesis,
convincing experimental evidence needs to be generated to sup-
port it. For example, the location and function of PCSK9 in athero-
sclerotic lesions can potentially be explored through tissue-speciﬁc
knockout mice or bone marrow transplantation experiments. It
will be necessary to observe the inﬂuence of PCSK9 on oxLDL up-
take in vitro, with binding, cell association, and lipoprotein degra-
dation assays. To further investigate the relationship between
PCSK9 and RCT, it will be important to establish an RCT model
in vivo to determine radiolabeled cholesterol levels in plasma,
the liver, bile acid, feces. Lastly, it will be necessary to verify the ef-
fect of PCSK9 on cholesterol efﬂux in vitro or ex vivo to evaluate
differences in the cholesterol efﬂux rate.
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